CRVS News and Press, Corvus Pharmaceuticals Inc.

2024-06-20 06:53:11 ET Summary Corvus Pharmaceuticals has shown positive growth and maturity over the past six months, with new leadership and increased clinical trial activity. The company is expanding its label and IP developments, with trials in oncology and immunology, as well...

2024-05-31 10:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the best ways to spot opportunities in penny stocks to buy is by following insiders. Most notably, insiders who are putting their money where their mouth is. After all, it’...

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-o...

2024-05-07 10:01:47 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...

2024-05-06 19:53:07 ET Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Conference Call May 06, 2024, 04:30 PM ET Company Participants Zack Kubow - Real Chemistry Richard Miller - President and CEO, Co-Founder Leiv Lea - Chief Financial Officer Jeffrey Ar...

Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Interim Data from Ciforade...

PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....

2024-05-03 17:20:12 ET More on Corvus Pharmaceuticals Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript Corvus stock gains amid pricing of $30.6M direct offering Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earni...

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and re...

2024-05-02 10:26:34 ET More on Corvus Pharmaceuticals Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Corvus Pharmaceuticals Historical earnings data for Corvus Pharmaceuticals Financial information ...